Last reviewed · How we verify
NCT03257670: BCLS
Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors
NA trial testing 4% Topical Lidocaine Gel in Dyspareunia in 70 participants. Status unknown.
1 January 2022
Quick facts
| Lead sponsor | University of Cincinnati |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 20 March 2018 |
| Primary completion | 1 January 2022 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 4% Topical Lidocaine Gel — full drug profile →
- CO2RE fractional laser therapy
Conditions studied
- Dyspareunia — all drugs for Dyspareunia →
Sponsor
University of Cincinnati
Who can join
18 and older, female only, with Dyspareunia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial seeks to determine if therapy with a CO2 laser to the vagina is more effective than lidocaine to the opening of the vagina before intercourse to reduce painful intercourse in women who are breast cancer survivors. This study will also be looking at whether or not the CO2 laser improves pelvic floor function, bowel and bladder function, and sexual function before and after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03257670
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dyspareunia
Currently open trials in the same condition.
- NCT06891690 — Use of TDCS Stimulation in Neurological and Gynaecological Conditions · NA · recruiting
- NCT06397885 — Prospective on Market Patient-reported Outcomes for Milli · active not recruiting
- NCT05761275 — Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach · NA · recruiting
- NCT05631665 — Genital Laser Treatment in Postmenopausal Patients · NA · active not recruiting
Other University of Cincinnati trials
Trials by the same sponsor.
- NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
- NCT07528638 — Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) · NA · not yet recruiting
- NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
- NCT07447895 — Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies · NA · not yet recruiting
- NCT07231588 — Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03257670 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cincinnati
- Last refreshed: 28 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03257670.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing